Evaluation of Annexin A7, Galectin-3 and Gelsolin as possible biomarkers of hepatocarcinoma lymphatic metastasis

YueGao,; Bai, Lulu; Ibrahim, Mohammed Mohammed; Ma, Wei; Zhang, Jun; Huang, Yühong; Wang, Bo; Lin, Shi; Tang, Jianwu

doi:10.1016/j.biopha.2013.12.009

Cited by 17 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectin-3 promotes tumor progression in HCC. In mice bearing HCC, the galectin-3 expression level in tumor tissue was significantly increased, while serum galectin-3 levels also demonstrated obvious changes ( 139 ). In an N-diethylnitrosamine-induced HCC mouse model, galectin-3 knockout mice developed a significantly smaller tumor burden with a less invasive phenotype compared with the wild-type animals.…”

Section: Galectin-3 and Cancermentioning

confidence: 99%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

Section: Galectin-3 and Cancermentioning

confidence: 99%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Indeed, the conflicting findings concerning Ezrin protein expression in cancer point to the direction that Ezrin expression in cancer is tissue or organ specific. A7 is a tumor suppressor and had been found to modulate several proteins in order to execute cancer suppressive role; among these proteins is Ezrin . The findings in this in vivo model suggest that A7‐up‐regulation inversely correlates with low Ezrin expression and tumor metastasis.…”

Section: Discussionmentioning

confidence: 79%

Ezrin as a possible diagnostic and/or prognostic biomarker in mice lymphatic metastatic hepatocellular carcinoma in vivo

et al. 2017

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) ranks in the top of cancers leading to death. Early diagnosis is the big challenge in the case of HCC. Our in vitro study showed that Ezrin expression in lymphatic metastasis hepatocellular carcinoma (LNM-HCC) was associated with the metastatic rate. Here we aim to evaluate Ezrin expression as diagnostic and/or prognostic biomarker of LNM-HCC in mice. Chinese inbred 615 mice, Hca-F and Hca-P cell lines were used in the study. Histological changes were determined by Hematoxylin and Eosin, while Ezrin expression was assessed by qRT-PCR, western blot, immunohistochemistry, and enzyme-linked immunosorbent assay. Ezrin expression in this study gives credit to our in vitro study which Ezrin expression was positively correlated with LNM-HCC and negatively with Annexin7 (A7) expression. The highest histological changes were observed in high metastatic primary/secondary tumors combined with high Ezrin expression. Ezrin and A7 are higher in total primary tumors than in total secondary tumors (P = 0.0001, P = 0.021), respectively. Ezrin expression was enhanced in Hca-P A7 down-regulated primary/secondary tumors (P = 0.004), whereas, Ezrin expression was suppressed in Hca-F A7 upregulated primary/secondary tumors. Serum ELISA indicated differential expression of Ezrin among the study groups (P ≤ 0.0001). Ezrin expression was higher in NC-Hca-F than NC-Hca-P (P ≤ 0.0001), suppressed in Hca-F A7 upregulation (P ≤ 0.0001) and in enhanced in Hca-P A7 down-regulation (P = 0.0001). In conclusion, Ezrin level may serve as a differential diagnostic and/or prognostic biomarker for high and low LNM-HCC and may be beneficial in the diagnosis of HCC disease. © 2017 BioFactors, 43(5):662-672, 2017.

show abstract

“…ALG-2 is a Ca 2+ -binding protein that belongs to the penta-EF-hand (PEF) protein family. In addition, galetin-3, a binding parter of ANXA7 has been identified previously in our laboratory and other laboratories as being involved in the development, progression invasion and metastasis of malignant tumor [9,[25][26][27]. Galetin-3 is an oncogenic protein with an anti-apoptotic activity, protection of mitochondrial integrity and down-regulation of caspases [25].…”

Section: Discussionmentioning

confidence: 99%

“…(Invitrogen, USA) supplemented with 200 mL/l fetal bovine serum (GIBCO, USA) at 37 8C in a humidified incubator (Thermo, USA) with 5% CO 2 [4,9].…”

Section: Cell Lines Culturementioning

confidence: 99%

Down-regulated expression of Annexin A7 induces apoptosis in mouse hepatocarcinoma cell line by the intrinsic mitochondrial pathway

Huang¹,

Du²,

Zhang³

et al. 2015

Biomedicine & Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

Evaluation of Annexin A7, Galectin-3 and Gelsolin as possible biomarkers of hepatocarcinoma lymphatic metastasis

Cited by 17 publications

References 24 publications

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Ezrin as a possible diagnostic and/or prognostic biomarker in mice lymphatic metastatic hepatocellular carcinoma in vivo

Down-regulated expression of Annexin A7 induces apoptosis in mouse hepatocarcinoma cell line by the intrinsic mitochondrial pathway

Contact Info

Product

Resources

About